I believe that the best oversight makes constructive recommendations to improve agency performance.
Henry Waxman
The Public Record
Henry Waxman is a former U.S. Representative from California, serving from 1975 to 2015. A member of the Democratic Party, he was known for his work on health care, environmental policy, and consumer protection. During his tenure, Waxman played a key role in the passage of the Affordable Care Act and was a prominent advocate for climate change legislation. He chaired the House Energy and Commerce Committee, where he focused on issues such as tobacco regulation and health care reform.
Well, these dire predictions never happened. Today House Republicans claim that the Clean Power Plan will cause a surge in electricity bills and effectively end coal use in America. This is just the same old scare tactic.
we certainly feel like we are under attack from Washington, DC, and if it is not a war, it sure is something that is pretty close to hell.
To me, it sounds like a lot of money, but that is not enough of a deterrent for a company with over $150 billion in revenue.
What I do take seriously is the need for good provider networks and robust benefit packages in the health insurance marketplaces.
The Affordable Care Act is the single most important step forward on this issue in the last 50 years.
What type of access does he have? If a mother has a policy that does not cover hospitalizations, what type of access does she have?
They want to go back to a world where health plans are free to offer policies that do not cover prescription drugs or hospitalization.
Thirty years ago, Representative Waxman coauthored the Hatch-Waxman Act, which updated our innovation ecosystem and made medications affordable for millions of Americans.
This MODDERN Cures proposal, the sponsors point out it is only for therapies that address an unmet medical need for serious or life-threatening diseases.
These core values represent a commitment that stretches all the way back to the founding of our country.
Our taxpayers want basic research to be funded through the National Institutes of Health, and I would assume everybody that cares about this problem is outraged when we see cuts at the NIH budget.
We cannot rest on our laurels. We have an obligation to periodically reevaluate and adjust to account for the sweeping changes in the health sector.
In a biosimilars provision in the Affordable Care Act, we gave 12 years of exclusivity to biologics.
We cannot legislate scientific advances. In some areas, the lack of new treatments is attributable to a lack of scientific knowledge, not the lack of incentives.
The good news is that innovation in this country is flourishing. More important new drugs are launched here than any place else in the world.